AnaptysBio
ANAB · Nasdaq · United States
Share price · ANAB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ANAB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 21 Oct 2026+5.5%
Nothing announced by ANAB that day or the session before.
- 20 Oct 2026-7.7%
- 20 Jul 2026-13.3%
Nothing announced by ANAB that day or the session before.
- 15 Jul 2026-10.7%
Nothing announced by ANAB that day or the session before.
- 14 Jul 2026-10.5%
Nothing announced by ANAB that day or the session before.
- 27 Apr 2026+13.1%
- 24 Apr 2026+14.8%
- 20 Apr 2026+13.2%
- 6 Apr 2026+8.2%
Nothing announced by ANAB that day or the session before.
- 27 Mar 2026-11.7%
Share of unusual movement by asset
For each asset, the share of ANAB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Imsidolimabevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 46% |
| Sessions with no dated event | — | 54% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | IL-36 receptorMonoclonal antibody | Psoriasis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $30M | — | $135M+ $18M short-term inv. | —-$9.5M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $26M | $34M | $248M+ $38M short-term inv. | $53M-$26M operating cash flow | report ↗ |
| 2025-Q3 | $76M | $31M | $110M+ $139M short-term inv. | —-$27M operating cash flow | report ↗ |
| 2025-Q2 | $22M | $38M | $44M+ $221M short-term inv. | $39M-$40M operating cash flow | report ↗ |
| 2025-Q1 | $28M | $41M | $99M+ $241M short-term inv. | $39M-$11M operating cash flow | report ↗ |
| 2024-Q3 | $30M | $42M | $192M+ $239M short-term inv. | $33M-$10M operating cash flow | report ↗ |
| 2024-Q2 | $11M | $42M | $72M+ $279M short-term inv. | $47M-$21M operating cash flow | report ↗ |
| 2024-Q1 | $7.2M | $37M | $54M+ $301M short-term inv. | $44M-$37M operating cash flow | report ↗ |
| 2023-Q3 | $3.3M | $31M | $26M+ $387M short-term inv. | $37M-$36M operating cash flow | report ↗ |
| 2023-Q2 | $3.5M | $33M | $35M+ $394M short-term inv. | $40M-$25M operating cash flow | report ↗ |
| 2023-Q1 | $1.4M | $35M | $95M+ $337M short-term inv. | $44M-$25M operating cash flow | report ↗ |
| 2022-Q3 | $1.3M | $22M | $59M+ $384M short-term inv. | $34M-$18M operating cash flow | report ↗ |
| 2022-Q2 | $1.2M | $21M | $72M+ $370M short-term inv. | $33M-$24M operating cash flow | report ↗ |
| 2022-Q1 | $1.0M | $23M | $166M+ $339M short-term inv. | $36M-$21M operating cash flow | report ↗ |
| 2021-Q3 | $21M | $22M | $336M+ $38M short-term inv. | $6.7M-$7.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $235M | — | $238M+ $73M short-term inv. | $3.3M$20M operating cash flow | report ↗ |
AnaptysBio reported full-year 2025 collaboration revenue of $234.6M, up 157.0% YoY from $91.28M, driven largely by Jemperli royalties and a $75M commercial sales milestone from GSK. R&D expenses were $136.0M for the year, down from $163.8M, and the company ended 2025 with cash and investments of $311.6M, including cash and equivalents of $238.2M. The company recorded a full-year net loss of $13.2M, or $0.46 per share.
The planned spin-off of its biopharma operations into First Tracks Biotherapeutics remains on track for Q2 2026, potentially as early as late-April. ANB033’s Phase 1b trial in celiac disease is ongoing and a cohort was initiated in eosinophilic esophagitis, with top-line data anticipated in Q4 2026 and 2027, respectively. GSK reported Jemperli Q4 2025 sales of $343M, up >13% quarter-over-quarter, implying a ~$1.4B annualized run rate, and Anaptys expects to achieve >$390M in annualized Jemperli royalties payable at GSK’s peak sales guidance of >$2.7B as early as 2029.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $91M | — | $123M+ $262M short-term inv. | $36M-$135M operating cash flow | report ↗ |
| 2023-FY | $17M | — | $36M+ $355M short-term inv. | $41M-$121M operating cash flow | report ↗ |
| 2022-FY | $10M | $89M | $71M+ $370M short-term inv. | $32M-$74M operating cash flow | report ↗ |
| 2021-FY | $63M | $99M | $496M+ $52M short-term inv. | $14M-$46M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($17.2M), 42 sales ($9.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-18 | EcoR1 Capital, LLC; NODELMAN OLEG · director, 10% owner; director, 10% owner | Open-market purchase | 138,093 | $46.54 | $6.4M | Form 4 |
| 2026-11-17 | EcoR1 Capital, LLC; NODELMAN OLEG · director, 10% owner; director, 10% owner | Open-market purchase | 152,367 | $45.66 | $7.0M | Form 4 |
| 2026-11-16 | EcoR1 Capital, LLC; NODELMAN OLEG · director, 10% owner; director, 10% owner | Open-market purchase | 84,120 | $45.66 | $3.8M | Form 4 |
| 2026-10-01 | RENTON HOLLINGS · director | Option exercise | 5,000 | $18.03 | $90K | Form 4 |
| 2026-10-01 | RENTON HOLLINGS · director | Open-market sale | 5,000 | $49.87 | $249K | Form 4 |
| 2026-10-01 | RENTON HOLLINGS · director | Option exercise (derivative) | 5,000 | — | — | Form 4 |
| 2026-09-15 | Orwin John A · director | Option exercise | 1,300 | — | — | Form 4 |
| 2026-09-15 | Orwin John A · director | Option exercise (derivative) | 1,300 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 206 reporting institutions held 28.2M shares ($1.5B, 95.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 7,880,094 | $437.0M |
| 2 | BlackRock, Inc. | 1,681,380 | $93.2M |
| 3 | TANG CAPITAL MANAGEMENT LLC | 1,330,879 | $73.8M |
| 4 | MORGAN STANLEY | 993,905 | $55.1M |
| 5 | STATE STREET CORP | 992,445 | $55.0M |
| 6 | Affinity Asset Advisors, LLC | 940,000 | $52.1M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 853,151 | $47.3M |
| 8 | Palo Alto Investors LP | 638,161 | $35.4M |
| 9 | 683 Capital Management, LLC | 625,000 | $34.7M |
| 10 | D. E. Shaw & Co., Inc. | 579,296 | $32.1M |
| 11 | First Light Asset Management, LLC | 565,431 | $31.4M |
| 12 | Sanofi | 821,917 | $30.4M |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 520,241 | $28.9M |
| 14 | VANGUARD PORTFOLIO MANAGEMENT LLC | 519,870 | $28.8M |
| 15 | BANK OF AMERICA CORP /DE/ | 501,086 | $27.8M |